11 research outputs found
Recommended from our members
Phase 1 cohort expansion of flotetuzumab, a CD123×CD3 bispecific Dart® protein in patients with relapsed/refractory acute myeloid leukemia (AML)
Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.
The following statement was posted on March 24, 2020 and updated April 2, 2020. It has been accepted for upcoming publication in the Journal for ImmunoTherapy of Cancer (JITC)